# A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)

> **NCT07755410** · PHASE2 · RECRUITING · sponsor: **Alkermes, Inc.** · enrollment: 312 (estimated)

## Conditions studied

- Attention Deficit Disorder With Hyperactivity (ADHD)

## Interventions

- **DRUG:** ALKS 7290
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07755410
- **Lead sponsor:** Alkermes, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-10
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 312 (ESTIMATED)
- **Last updated:** 2026-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07755410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07755410, "A Study to Evaluate Safety and Efficacy of ALKS 7290 Compared With Placebo in Adult Participants With Attention Deficit Hyperactivity Disorder (ALKS 7290-201)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07755410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*